Paladin Labs Acquires Binotal(R) in Latin America From Bayer

Paladin Labs Acquires Binotal(R) in Latin America From Bayer 
MONTREAL, CANADA -- (Marketwired) -- 07/02/13 -- Paladin Labs Inc.
(TSX:PLB), a leading Canadian specialty pharmaceutical company, today
announced that it has signed an agreement with Bayer to acquire
Binotal(r) for Latin America including Mexico, Brazil, Columbia,
Ecuador and select countries in Central America. Bayer will be
providing certain distribution support services for an interim
Binotal(r) (ampicillin trihydrate) has been sold in the region for
over 40 years. It has a strong market position for the systemic
treatment of bacterial infections at a wide variety of sites with
varying severity. In 2012, Binotal(r) recorded sales of over CAD $11
million in Latin America with Mexico and Brazil representing over
two-thirds of the sales. Financial details related to the agreement
were not disclosed. 
"Binotal(r) is a proven product with a long history of efficacy and
safety in improving the lives of people suffering from bacterial
infections," said Mark Beaudet, interim President and CEO of Paladin
Labs Inc. "The product has strong brand recognition and strategically
ties-in with our desire to grow our business in Latin America. Added
to our existing product portfolio, Binotal(r) will provide additional
critical mass and strategic options for further developing our
operations in Latin America."  
About Paladin Labs Inc.  
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing
innovative pharmaceutical products for the Canadian and world
markets. With this strategy, a focused national sales team and proven
marketing expertise, Paladin has evolved into one of Canada's leading
specialty pharmaceutical companies. Paladin's shares trade on the
Toronto Stock Exchange under the symbol PLB. For more information
about Paladin, please visit the Company's web site at 
This press release may contain forward-looking statements and
predictions. These forward-looking statements, by their nature,
necessarily involve risks and uncertainties that could cause actual
results to differ materially from those contemplated by the
forward-looking statements. The Company considers the assumptions on
which these forward-looking statements are based to be reasonable at
the time they were prepared, but cautions that these assumptions
regarding the future events, many of which are beyond the control of
the Company and its subsidiaries, may ultimately prove to be
incorrect. Factors and risks, which could cause actual results to
differ materially from current expectations, are discussed in the
annual report as well as in the Company's Annual Information Form for
the year ended December 31, 2012. The Company disclaims any intention
or obligation to update or revise any forward-looking statements
whether as a result of new information or future events and except as
required by law. For additional information on risks and
uncertainties relating to these forward-looking statements, investors
should consult the Company's ongoing quarterly fillings, annual
report and Annual Information Form and other fillings found on SEDAR
Samira Sakhia, MBA, CPA, CA
Chief Financial Officer
Paladin Labs Inc.
514-344-4675 (FAX)
Press spacebar to pause and continue. Press esc to stop.